PNC Financial Services Group Inc. lowered its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 11.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,836 shares of the specialty pharmaceutical company’s stock after selling 1,766 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Jazz Pharmaceuticals PLC were worth $2,153,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in JAZZ. BlackRock Inc. lifted its position in shares of Jazz Pharmaceuticals PLC by 3,163.9% in the 1st quarter. BlackRock Inc. now owns 3,215,159 shares of the specialty pharmaceutical company’s stock worth $466,615,000 after buying an additional 3,116,652 shares during the last quarter. Janus Capital Management LLC boosted its holdings in shares of Jazz Pharmaceuticals PLC by 46.8% in the 1st quarter. Janus Capital Management LLC now owns 1,470,245 shares of the specialty pharmaceutical company’s stock valued at $213,367,000 after buying an additional 468,940 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Jazz Pharmaceuticals PLC by 41.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after buying an additional 410,031 shares during the period. American Century Companies Inc. boosted its holdings in shares of Jazz Pharmaceuticals PLC by 133.2% in the 2nd quarter. American Century Companies Inc. now owns 549,900 shares of the specialty pharmaceutical company’s stock valued at $85,509,000 after buying an additional 314,094 shares during the period. Finally, Teachers Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals PLC by 116.4% in the 1st quarter. Teachers Advisors LLC now owns 326,917 shares of the specialty pharmaceutical company’s stock valued at $47,445,000 after buying an additional 175,861 shares during the period. Hedge funds and other institutional investors own 88.34% of the company’s stock.

WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/pnc-financial-services-group-inc-cuts-holdings-in-jazz-pharmaceuticals-plc-jazz/1604793.html.

In other news, Director Paul L. Berns sold 662 shares of the stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $142.37, for a total transaction of $94,248.94. Following the sale, the director now directly owns 6,599 shares of the company’s stock, valued at $939,499.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Suzanne Sawochka Hooper sold 4,580 shares of the stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $160.00, for a total transaction of $732,800.00. Following the sale, the executive vice president now directly owns 32,322 shares in the company, valued at $5,171,520. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,297 shares of company stock valued at $1,279,417. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals PLC (JAZZ) opened at 150.13 on Tuesday. The firm’s 50-day moving average price is $148.43 and its 200-day moving average price is $151.39. The company has a market capitalization of $9.02 billion, a price-to-earnings ratio of 23.13 and a beta of 1.05. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.13). The company had revenue of $394.39 million for the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the company earned $2.67 EPS. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post $10.88 earnings per share for the current year.

JAZZ has been the subject of a number of recent research reports. Deutsche Bank AG reaffirmed a “buy” rating and set a $176.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, July 4th. Vetr raised shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 target price on the stock in a report on Tuesday, June 6th. Piper Jaffray Companies set a $182.00 target price on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Friday, July 14th. Royal Bank Of Canada restated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 9th. Finally, Mizuho downgraded Jazz Pharmaceuticals PLC from a “buy” rating to a “neutral” rating and decreased their target price for the company from $162.00 to $150.00 in a research note on Tuesday, July 4th. One analyst has rated the stock with a sell rating, four have given a hold rating and eighteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $180.91.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.